Inhibition of CD11b/CD18 desialylation may represent a promising therapeutic strategy for reducing dysregulated PMN influx and associated mucosal tissue damage in chronic inflammatory disorders, including COPD and IBD. This evidence concerns the gene ITGB2 and chronic obstructive pulmonary disease.